Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.66 USD
Change Today -0.34 / -6.80%
Volume 481.0
RLMDD On Other Exchanges
Symbol
Exchange
OTC US
As of 5:20 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

relmada therapeutics inc (RLMDD) Snapshot

Open
$4.70
Previous Close
$5.00
Day High
$4.70
Day Low
$4.66
52 Week High
10/29/14 - $20.00
52 Week Low
08/24/15 - $4.11
Market Cap
50.1M
Average Volume 10 Days
9.6K
EPS TTM
--
Shares Outstanding
10.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RELMADA THERAPEUTICS INC (RLMDD)

Related News

No related news articles were found.

relmada therapeutics inc (RLMDD) Related Businessweek News

No Related Businessweek News Found

relmada therapeutics inc (RLMDD) Details

Relmada Therapeutics, Inc., a clinical stage biopharmaceutical company, focused on the development of drug products for the treatment of pain in the United States. Its lead development projects include LevoCap ER, a proprietary once-a-day extended release (ER) dosage form of the potent opioid levorphanol in a tamper resistant drug delivery system; and D-Methadone, a d-optical isomer of racemic methadone and an antagonist at the N-methyl-D-aspartate receptor that provides relief to patients with neuropathic pain and to reduce analgesic tolerance to opioids. The company is also developing BuTab ER, a proprietary ER oral dosage form of the DEA Schedule III opioid, buprenorphine, which carries reduced risk of physical dependence, euphoria, and certain opioid side effects; and MepiGel, a proprietary topical non-greasy gel dosage form of the local anesthetic mepivacaine for the treatment of postherpetic neuralgia and painful HIV-associated neuropathy. The company was founded in 2004 and is based in New York, New York.

7 Employees
Last Reported Date: 11/17/14
Founded in 2004

relmada therapeutics inc (RLMDD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $182.5K
Chief Financial Officer
Total Annual Compensation: $140.0K
Compensation as of Fiscal Year 2014.

relmada therapeutics inc (RLMDD) Key Developments

Relmada Therapeutics, Inc. Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist

Relmada Therapeutics, Inc. announced that it has received a No Objection Letter from Health Canada to conduct a multiple ascending dose clinical study with d-Methadone, its novel, N-methyl-D-aspartate receptor antagonist being developed for the treatment of neuropathic pain. The aim of the completed study was to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of oral single ascending doses of d-Methadone in healthy subjects in order to establish a Maximum Tolerated Dose. In the planned second study, healthy subjects will receive daily doses of the product over several days based on the established MTD. The data from these studies will inform the design of a subsequent Phase 2 proof of concept study in neuropathic pain.

Relmada Therapeutics, Inc. Amends and Restated Bylaws

Effective as of August 6, 2015, the Board of Relmada Therapeutics, Inc. amended and restated Bylaws. Among other things, the amended and restated Bylaws amendment establishes advance notice requirements for nominations for election to the company’s board of directors and for proposals of business to be acted upon at stockholder meetings.

Relmada Therapeutics, Inc. Appoints Charles J. Casamento to its Board of Directors

Relmada Therapeutics, Inc. announced that Charles J. Casamento has joined the company's board of directors, completing the slate of three independent directors. Mr. Casamento will also serve as chairman of the audit committee for Relmada Therapeutics. Since 2007 Mr. Casamento has been executive director and principal of The Sage Group.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RLMDD:US $4.66 USD -0.34

RLMDD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RLMDD.
View Industry Companies
 

Industry Analysis

RLMDD

Industry Average

Valuation RLMDD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 21.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RELMADA THERAPEUTICS INC, please visit www.relmada.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.